6 Nov 2017 BAARN (Boston Area Antimicrobial Resistance Network) + 7-8 Nov BARDA Industry Days

Dear All:

Early November will be busy! First, BAARN is having their annual meeting in the Boston area on 6 Nov. See below a note from Michael Gilmore with details. If you are in Boston on that day, I highly recommend this meeting as a superb scientific event & networking opportunity.

Second, you can then go from BAARN to BARDA’s Industry Days in DC on 7-8 Nov. Here’s the registration link for more details. This is an opportunity to learn about BARDA’s strategic goals for FY18 and beyond while networking with members of ASPR, BARDA, AMCG and other government and industry stakeholders. If you are consider US government funding, this is a great way to learn about working with BARDA and its USG partners.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Mike writes: Tickets for the 2017 annual Boston Area Antibiotic Resistance Network meeting are now available at this link. The event will be on 6 Nov 2017 at the American Academy of Arts and Science’s Norton Woods Conference Center, adjacent to the Harvard campus (200 Beacon St., Somverville MA). The auditorium is limited to 200 attendees, so register early and notify friends and associates you know to be interested.

In response to feedback from last year, there will be more opportunity for 1-on-1 networking throughout the day. There will also be a rapid fire session for new biotechs to introduce their new efforts to the community.

The program:
8:00 – 8:30 Registration
8:30  Welcome

8:35 Session I: Advances in new therapeutics
10:15 – 11:00 Networking over coffee

11:00  Session II: Advances in alternatives to antibiotics for managing host microbe interactions
12:15 Lunch and more networking

2:00  Session III: Advances in Diagnostics
3:40 – 4:00 Short Break

4:00  Federal resources that can help (NIH Research Resources & Translational. Research DMID)
4:30  Short poster pitches from select treatment or diagnostic biotech startups

5:15 Networking and posters
7:00 Adjourn

​——————————
Upcoming meetings of interest to the AMR community:

Share

How economists (and Finance Ministers) think…

Dear All, Anthony McDonnell and his colleagues at CGD (Center for Global Development) have just released a truly lovely paper on the economics of antibiotic resistance. What makes this one special is that the paper dissects the problem of AMR through an economist’s spectacles in a way that is very accessible to the non-expert. You

The road to UNGA 2024 is paved with … reports!

Dear All, We’re now well into the run-up to the HLM (High-Level Meeting) on AMR during UNGA 2024 (the UN General Assembly, September 2024, see the 15 Apr 2023 newsletter for details). In preparation, reports providing data to support policy and decision-making are continuing to appear. Today, for example, GCOA and IDSA released their report entitled “2024

Leaving the lab: The decline in AMR R&D professionals

Dear All, The AMR Industry Alliance has today released a fascinating and disturbing report. Entitled “Leaving the Lab: Tracking the Decline in AMR R&D Professionals” (press release, report itself), its key message of “Researchers Are Leaving the AMR Field – Even as the Threat Rapidly Grows” is illustrated vividly by the report’s graphics. I’m going

ADVANCE-ID seeks antibiotic for P2/3 development Asia!

Dear All, Yow! Led by David Paterson,  ADVANCE-ID (ADVANcing Clinical Evidence in Infectious Diseases) is a research group launched March 2023 as a network of more than 30 hospitals across Asia. The exciting news is that ADVANCE-ID have just announced that they are seeking a novel antimicrobial agent vs. MDR Gram-negatives that could be advanced in the clinic

Scroll to Top